Karl Ploessl
Overview
Explore the profile of Karl Ploessl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
940
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhao R, Lv J, Li M, Xu S, Liang W, Lin X, et al.
Eur J Nucl Med Mol Imaging
. 2024 Oct;
52(3):925-935.
PMID: 39419848
Purpose: Bisphosphonates are pivotal in managing bone tumors by inhibiting bone resorption. This study investigates the therapeutic potential of [Lu]Lu-P15-073, a novel bisphosphonate, for radioligand therapy (RLT) in bone metastases....
2.
Zhao R, Chen J, Ye T, Chu J, Li J, Zhang Y, et al.
EJNMMI Radiopharm Chem
. 2024 Oct;
9(1):71.
PMID: 39412702
Background: In the central nervous system, type 2 vesicular monoamine transporters (VMAT2) are responsible for the reuptake of monoamines from synaptic junction back to pre-synaptic terminal vesicles. These transporters are...
3.
Wang R, Jin W, Luo Y, Hong H, Zhao R, Li L, et al.
Mol Pharm
. 2024 Jun;
21(7):3256-3267.
PMID: 38856975
Prostate-specific membrane antigen (PSMA) overexpressed in prostate cancer cells can serve as a target for imaging and radioligand therapy (RLT). Previously, [Ga]Ga-P16-093, containing a Ga(III) chelator, ,'-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-,'-diacetic acid (HBED-CC), displayed...
4.
Li L, Wang J, Wang G, Wang R, Jin W, Zang J, et al.
Eur J Nucl Med Mol Imaging
. 2024 Apr;
51(9):2794-2805.
PMID: 38658392
Purpose: Prostate-specific membrane antigen (PSMA) is a promising target for diagnosis and radioligand therapy (RLT) of prostate cancer. Two novel PSMA-targeting radionuclide therapy agents, [Lu]Lu-P17-087, and its albumin binder modified...
5.
Jin W, Zhao R, Wang R, Choi S, Ploessl K, Alexoff D, et al.
J Med Chem
. 2024 Mar;
67(6):4793-4803.
PMID: 38450559
Bone metastasis in cancer patients is a major disease advancement for various types of cancer. Previously, [Ga]Ga-HBED-CC-bisphosphonate ([Ga]Ga-P15-041) showed excellent bone uptake and efficient detection of bone metastasis in patients....
6.
Alexoff D, Choi S, Ploessl K, Kim D, Zhao R, Zhu L, et al.
EJNMMI Radiopharm Chem
. 2024 Feb;
9(1):15.
PMID: 38393404
Background: Recent advancements in positron emission tomograph (PET) using prostate specific membrane antigen (PSMA)-targeted radiopharmaceuticals have changed the standard of care for prostate cancer patients by providing more accurate information...
7.
Zhao R, Ke M, Lv J, Liu S, Liu Y, Zhang J, et al.
Eur J Nucl Med Mol Imaging
. 2024 Jan;
51(6):1753-1762.
PMID: 38212531
Purpose: This is a first-in-human study to evaluate the radiation dosimetry of a new prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical, [F]AlF-P16-093, and also initial investigation of its ability to detect PSMA-positive...
8.
Zha Z, Ploessl K, Choi S, Zhao R, Jin W, Wang R, et al.
J Med Chem
. 2023 Sep;
66(17):12602-12613.
PMID: 37670407
Prostate-specific membrane antigen (PSMA) is an excellent target for imaging and radionuclide therapy of prostate cancer. Recently, [Lu]Lu-PSMA-617 (Pluvicto) was approved by the FDA for radionuclide therapy. To develop hetero-bivalent...
9.
Hong H, Zha Z, Zhao R, Luo Y, Jin W, Li L, et al.
Mol Pharm
. 2023 Mar;
20(4):2159-2169.
PMID: 36942924
Fibroblast activation protein (FAP) is selectively expressed in tumors and highly important for maintaining the microenvironment in malignant tumors. Radioisotope-labeled FAP inhibitors (FAPIs) were proven to be useful for diagnosis...
10.
Zha Z, Choi S, Li L, Zhao R, Ploessl K, Yao X, et al.
J Med Chem
. 2022 Sep;
65(19):13001-13012.
PMID: 36103652
Prostate-specific membrane antigen (PSMA) is a promising target for the diagnosis and radionuclide therapy of prostate cancer. This study reports conversion of a previously reported Ga-imaging agent, [Ga]Ga-P16-093, to a...